Frontrunner Kymera Claims Proof-Of-Concept For Protein Degrader Platform

Results From Sanofi-Partnered Asset

 
• By Andrew McConaghie

Kymera has unveiled the first placebo-controlled data from a protein degradation candidate, adding to heightened expectations for the novel modality.

MIT Hockfield Court, Stata Center in Kendall Square, Cambridge MA
Cambridge, MA -based Kymera has reached 'proof of concept' six years after its launch. • Source: Alamy

More from Immunological

More from Therapy Areas